Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
Sponsor: University of Jordan
Summary
Autologous bone marrow-derived mesenchymal cells will be injected into patients diagnosed with premature ovarian failure
Official title: The Use of Expanded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans: Phase I Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 38 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2022-01-01
Completion Date
2027-01-31
Last Updated
2025-01-28
Healthy Volunteers
No
Conditions
Interventions
expanded autologous bone marrow derived MSC Intravaginally
Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
expanded autologous bone marrow derived MSC Laporoscopic
Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
EV
Extracellular vesicles injection
Locations (1)
Cell Therapy Center, University of Jordan
Amman, Jordan